DR LAL PATHLABS
|
DR LAL PATHLABS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 58.28 | 42.85 | 28.65 | 41.37 | 34.99 |
| CEPS(Rs) | 75.87 | 60.60 | 46.93 | 55.00 | 44.83 |
| DPS(Rs) | 24.00 | 24.00 | 12.00 | 12.00 | 20.00 |
| Book NAV/Share(Rs) | 253.14 | 215.40 | 192.88 | 173.17 | 144.61 |
| Tax Rate(%) | 21.21 | 28.32 | 29.88 | 26.25 | 24.83 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 28.26 | 27.36 | 24.29 | 26.86 | 27.59 |
| EBIT Margin(%) | 26.29 | 24.02 | 18.91 | 24.20 | 25.95 |
| Pre Tax Margin(%) | 25.38 | 22.70 | 17.05 | 22.75 | 24.94 |
| PAT Margin (%) | 20.00 | 16.27 | 11.95 | 16.78 | 18.75 |
| Cash Profit Margin (%) | 25.76 | 22.72 | 19.40 | 21.96 | 23.63 |
| Performance Ratios | |||||
| ROA(%) | 19.53 | 15.23 | 10.36 | 17.77 | 19.87 |
| ROE(%) | 25.15 | 21.27 | 15.80 | 26.45 | 26.89 |
| ROCE(%) | 31.53 | 27.89 | 20.34 | 32.67 | 36.03 |
| Asset Turnover(x) | 0.98 | 0.94 | 0.87 | 1.06 | 1.06 |
| Sales/Fixed Asset(x) | 1.32 | 1.22 | 1.14 | 1.73 | 2.51 |
| Working Capital/Sales(x) | 2.56 | 3.36 | 4.01 | 5.56 | 1.82 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.76 | 0.82 | 0.88 | 0.58 | 0.40 |
| Receivable days | 12.27 | 12.15 | 14.14 | 13.30 | 13.63 |
| Inventory Days | 5.45 | 5.83 | 7.81 | 8.31 | 11.49 |
| Payable days | 146.09 | 138.53 | 123.86 | 105.92 | 120.30 |
| Valuation Parameters | |||||
| PER(x) | 42.52 | 52.80 | 63.80 | 63.02 | 77.38 |
| PCE(x) | 32.66 | 37.34 | 38.95 | 47.40 | 60.39 |
| Price/Book(x) | 9.79 | 10.50 | 9.48 | 15.06 | 18.72 |
| Yield(%) | 0.97 | 1.06 | 0.66 | 0.46 | 0.74 |
| EV/Net Sales(x) | 8.08 | 8.15 | 7.34 | 10.28 | 13.68 |
| EV/Core EBITDA(x) | 25.19 | 26.74 | 27.86 | 34.99 | 44.38 |
| EV/EBIT(x) | 30.72 | 33.92 | 38.83 | 42.48 | 52.73 |
| EV/CE(x) | 9.15 | 9.39 | 7.78 | 9.29 | 17.38 |
| M Cap / Sales | 8.42 | 8.48 | 7.56 | 10.41 | 14.27 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 10.54 | 10.40 | -3.38 | 32.01 | 18.86 |
| Core EBITDA Growth(%) | 16.31 | 27.63 | -13.32 | 25.77 | 22.32 |
| EBIT Growth(%) | 21.00 | 40.24 | -24.51 | 23.09 | 25.96 |
| PAT Growth(%) | 35.87 | 50.28 | -31.18 | 18.15 | 30.27 |
| EPS Growth(%) | 35.99 | 49.58 | -30.75 | 18.25 | 29.07 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | 0.05 | 0.15 | 0.24 | - |
| Current Ratio(x) | 3.39 | 2.43 | 2.07 | 1.75 | 4.18 |
| Quick Ratio(x) | 3.30 | 2.35 | 2.00 | 1.65 | 4.02 |
| Interest Cover(x) | 29.01 | 18.22 | 10.16 | 16.74 | 25.65 |
| Total Debt/Mcap(x) | - | - | 0.02 | 0.02 | - |
Compare Financial Ratios of peers of DR LAL PATHLABS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| DR LAL PATHLABS | ₹26,606.9 Cr | 4.7% | 15.3% | 1.9% | Stock Analytics | |
| MAX HEALTHCARE INSTITUTE | ₹121,222.0 Cr | -0.8% | -4.2% | 34.9% | Stock Analytics | |
| APOLLO HOSPITALS ENTERPRISE | ₹105,597.0 Cr | -0.2% | -2.9% | 13.1% | Stock Analytics | |
| FORTIS HEALTHCARE | ₹64,869.8 Cr | 1.5% | 8.1% | 70.9% | Stock Analytics | |
| NARAYANA HRUDAYALAYA | ₹39,715.5 Cr | -2.3% | -3.2% | 52.3% | Stock Analytics | |
| GLOBAL HEALTH | ₹35,962.8 Cr | -1% | 12.3% | 5.7% | Stock Analytics | |
DR LAL PATHLABS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| DR LAL PATHLABS | 4.7% |
15.3% |
1.9% |
| SENSEX | -1.1% |
-3.4% |
-1.1% |
You may also like the below Video Courses
